It is still unclear whether there are clinically exploitable differences in the biology and behaviour of early versus late relapses in diffuse large B-cell lymphoma (DLBCL). The present study aimed to analyse a large populationbased DLBCL cohort in order to identify (i) the frequency of late relapses (LR), (ii) parameters influencing the risk of LR, and (iii) the impact of introducing rituximab on the occurrence of LR. The data of 7247 DLBCL patients was obtained from the Danish Lymphoma Group Registry. Patients with LR had a lower International Prognostic Index and better performance score than early relapse (ER) patients. The use of radiotherapy lowered only the rate of ER while the use of rituximab yielded a lower occurrence of both ER and LR (P < 0Á0001 and P < 0Á0001, respectively), possibly suggesting a longer-lasting biological effect. Additionally, we found a female overrepresentation among LR patients that had received a rituximab-containing first line treatment. It was found that patients with LR had a significantly better 5-year overall survival compared to ER patients. In conclusion, LR was more frequently associated with low-risk features than ER. Furthermore, we found that the use of modern immunochemotherapy regimens in DLBCL lowers the risk of both ER and LR.
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of malignant lymphoma with an estimated incidence rate of 8/100 000 (Dansk Lymfomgruppe 2012) . DLBCL is an aggressive lymphoproliferative disease that inflicts a considerable degree of symptoms, causing a vast number of patients to seek medical attention at reasonably early stages of the disease. Because of this, and due to the high sensitivity to chemotherapy, some two-thirds of patients can potentially be cured (Feugier et al, 2005; Reyes et al, 2005) .
Nevertheless, approximately 30-40% (Friedberg, 2011) of DLBCL patients achieving complete remission (CR) will experience a relapse of the disease. The majority of these patients will relapse within the first 1-2 years (Lee et al, 1997; Sanz et al, 1998) and 10-20% will achieve a second CR with salvage treatment (Gisselbrecht et al, 2012) . However, a subset of all patients will suffer a late relapse, i.e. several years after achievement of CR. Little is known about the population-based frequency of late-onset recurrences and about the factors predisposing to their occurrence.
There is no consensus on the definition of late relapse in lymphoproliferative disease, with the cut-off for relapse ranging from 24 months to 5 years after start of treatment or achievement of CR. Similarly, results from previous studies on factors enhancing the risk of a late relapse have diverged considerably (Vose et al, 2010; Larouche et al, 2010; Ko & Yuen, 2002; Sanz et al, 1998; Table SI) . Whether there are therapeutically exploitable differences in the biology and clinical behaviour in disease of patients with late relapse versus patients with sustained CR or early relapse, still remains to be determined.
The aim of the present study was to characterise the occurrence and identify factors associated with relapse occurring 5 years or more after achieving first CR (CR1) for patients with DLBCL. We performed a population-based retrospective study, based on information entered into the Danish Lymphoma Group Registry (LYFO) (El-Galaly et al, 2015; Arboe et al, 2016) , including all patients diagnosed with DLBCL in the period 1983-2014. More specifically, the present study aimed at identifying (i) the overall frequency of late relapse, (ii) clinical and paraclinical parameters influencing the risk of late relapse and (iii) the impact of introducing rituximab on the occurrence of late relapse.
Methods

Study population
The LYFO registry prospectively collects clinical and pathological data on all Danish lymphoma patients from diagnosis until death, thereby minimising selection bias (Arboe et al, 2016) . The registry is routinely merged with the Danish Cancer Registry (DCR), which in turn is updated with information on all cancers in Denmark since 1942 (Gjerstorff, 2011) . The present study included all patients recorded in the LYFO registry with a diagnosis of DLBCL between 1 January 1983 and 8 July 2014. CR and unconfirmed CR were defined according to the 1999 Cheson criteria (Cheson et al, 2007) , and the date of CR was uniformly assigned to 6 months after diagnosis to allow for treatment finalisation.
Late relapse was defined as a biopsy-proven reoccurrence of disease more than 5 years after achievement of CR1. Correspondingly, the disease-free interval required in order to fulfil the definition of an early relapse was a maximum of 2 years after achievement of CR1. In order to more clearly separate features associated with early relapse from those associated with late events, an intermediate patient group with relapse occurring between 2 and 5 years from CR1 (n = 184) was excluded from the analysis. In all cases of relapse, the diagnosis was histologically verified on the basis of an excisional or core needle biopsy. Continuous complete remission (cCR) was defined as maintenance of remission without evidence of lymphoma reoccurrence. In order to minimise bias we excluded more recently diagnosed patients who had not sustained a CR for a minimum of 5 years after end of treatment.
All study subjects were followed from the date of lymphoma diagnosis until death or the end of the study period (8 July 2014), whichever occurred first. Clinical and paraclinical features as well as information on treatment regimens were obtained from the LYFO registry.
The study was approved by the regional ethical board of The Region of Central Denmark (record no. 1-10-72-39-14) and The Danish Data Protection Agency (record no. 1-16-02-109-14) and was performed in accordance with the Helsinki Declaration.
Statistical analysis
Distribution differences of clinical characteristics between groups were analysed using Pearson 0 s v 2 test, and associations between treatment modalities and type of relapse were evaluated using logistic regression. Outcome was evaluated by Kaplan-Meier time-to-event analysis and compared using the log-rank test. Overall survival (OS) after relapse was defined as time from confirmed diagnosis of relapse until death from any cause, latest follow-up, or end of study, whichever occurred first. For late relapses as primary event of interest, the independent prognostic value of predefined clinically relevant biomarkers and factors showing a crude association with P < 0Á1 and proportional hazards between groups, were tested in a multivariate Cox regression model. All P-values were 2-sided and values were regarded statistically significant if P < 0Á05.
Results
Population characteristics
We identified 7247 patients from the LYFO registry diagnosed with DLBCL between 1 January 1983 and 8 July 2014. Of these, 4097 (57%) were reported as having achieved a CR upon first line treatment. No relapse was reported in 3279 (80%) of these patients, and they were said to be in cCR. However, 1379 patients were excluded from the cCR group as they had received more recent treatment and consequently upheld a CR for less than 5 years, wherefore 1900 (46% of all patients in CR) were defined as in cCR. Conversely, 818 patients (20%) had a registered relapse. Amongst relapsed patients, 78 (10% of all relapses) relapsed more than 5 years after CR (late relapses) and 556 (68% of all relapses) had an early relapse. Patients with incomplete data on treatment response were excluded from the study. The mean follow-up from time of diagnosis until death or end-of-study was 6Á8 years (range 0-31Á1) for all eligible patients (i.e. patients achieving a CR).
Patients experiencing an early relapse had a median age of 63Á7 years (range 17-90), while the median age of patients with a late relapse was 63 years (range 27-86). The male:female ratio was 1Á2 and 1Á1 for early and late relapse, respectively. Non-relapsing patients had a median age of 59Á1 years (range 16-94) and a male:female ratio of 1Á2. The differences found for age and genders between the three groups were non-significant.
Detailed clinical, paraclinical, and treatment characteristics are shown in Tables I and II .
Risk factors
We compared characteristics of patients with late relapse to patients with early relapse and patients in sustained CR (cCR). Patients with late relapse presented with a more favourable International Prognostic Index (IPI) (P = 0Á019) and better World Health Organisation (WHO) performance score (P = 0Á004) compared to early relapse patients. No significant differences in these characteristics were found between patients with late relapse and patients with cCR. Lactate dehydrogenase (LDH) elevation at the time of initial diagnosis was found more frequently in all relapse patients (early and late alike) compared to patients in cCR (P < 0Á0001 and P < 0Á0001, respectively), while no difference was observed when comparing LDH elevation in patients within the two relapse groups (P = 0Á240). Furthermore, bone marrow involvement of lymphoma at time of diagnosis was found more often in patients with a subsequent late relapse than in patients with cCR (P = 0Á039). No other statistically significant clinical or paraclinical differences were observed when comparing patients with late relapse to patients with early relapse and non-relapsing patients (Table I) .
Focusing on treatment modalities, the use of radiotherapy was associated with a lower risk of successively having an early relapse compared to a late relapse (Odds ratio [OR] 2Á42 [95% confidence interval (CI) 1Á27-4Á61] P = 0Á007).
Similarly, compared to patients who maintained a CR, the occurrence of early relapse was seen more frequently amongst patients who did not receive radiotherapy upfront (OR 0Á65 [95% CI 0Á47-0Á90] P = 0Á009). All estimates were adjusted for Ann Arbor stage.
The use of rituximab significantly lowered the occurrence of both early (OR 0Á17 [0Á12-0Á23]; P < 0Á0001) and late relapse (OR 0Á24 [0Á13-0Á44]; P < 0Á0001). This finding was still present when adjusting for gender, Ann Arbor stage and radiotherapy in the analysis. When combining treatment modalities, we found that a treatment plan including both rituximab and radiotherapy reduced the risk of both early (OR 0Á31 [0Á20-0Á49]; P < 0Á0001) and late relapse (OR 0Á33 [0Á12-0Á95]; P = 0Á041), while there was no significant (Table II ). An interesting additional finding was a significant female overrepresentation among late relapsing patients who received a rituximab-containing first line treatment compared to patients in cCR (P = 0Á031) (Fig 1) . In a multivariate Cox regression analysis with late relapse as primary event of interest, no clinical features were significantly associated with patients having a late relapse compared to patients in sustained CR. However, compared to patients with early relapse both administration of radiotherapy, Ann Arbor stage and age had prognostic influence (Table III) .
With regard to outcome we found that DLBCL patients with late relapse had a significantly better 5-year OS compared to patients with early relapse, i.e. late relapse 42% [95% CI 30-54%] versus early relapse 20% [95% CI 16-23%] (P < 0Á0001) (Fig 2A) , all estimates computed from day of relapse. The difference in outcome was no longer present for those patients who had received rituximab-containing first line treatment (Fig 2B) .
Characteristics of late relapse patients
A total of 78 patients with late relapse were identified. The range of time in remission for late-relapsing patients was 5Á5-16Á6 years with a median of 7Á2 years. Patient records for the subgroup treated at Aarhus University Hospital (N = 15) were reviewed and clinical characteristics at time of relapse are presented. In 9 out of 15 patients, relapse occurred at a different anatomical localisation than at time of diagnosis. In 8 patients, the reoccurrence presented with disseminated disease (Ann Arbor stage III or IV), while the remaining 7 patients relapsed with localised disease. In 12 patients, the biopsy at time of relapse revealed a DLBCL histology while 3 patients displayed a more indolent histology (follicular lymphoma, N = 2, and Waldenstr€ om macroglobulinaemia/immunocytoma, N = 1). Eleven patients achieved a second CR, 1 reached partial remission (PR), 2 died of disease progression and 1 is alive with evidence of Waldenstr€ om macroglobulinaemia.
Discussion
In this population-based cohort of patients with DLBCL we identified both patient-specific and treatment-related factors with influence on the occurrence of late relapse. In accordance with some previous reports, we found patients with late reoccurrence of lymphoma after first line treatment for DLBCL to have more favourable prognostic characteristics, e.g. lower IPI and better WHO performance status at time of diagnosis, compared to patients with early relapse of disease (Larouche et al, 2010; Vose et al, 2010) . However, we did not find a statistically significant difference when comparing (90) 460 (83) 63 (81) P = 0Á167 P = 0Á996 Other 108 (6) 51 (9) 7 (9) Unknown 89 (5) 45 (8) 8 (10) cCR, continuous complete remission; CHOP, cyclophosphamide, adriamycin, vincristine and prednisolone; DLBCL, diffuse large B-cell lymphoma; ER, early relapse; LR, late relapse.
these clinical factors of patients with late relapse to patients who stayed in CR (Table II) . This could suggest differences in the biological mechanisms responsible for early and late reoccurrence of DLBCL, respectively. It is possible that early lymphoma relapse may reflect the presence of minimal residual disease (MRD) at the end of treatment whereas late relapse, particularly with the long lag-time used to define late events in our study (>5 years), more likely reflects a late reappearance of 'de novo disease', possibly on the basis of clonal instability. This would be in keeping with our observation that radiotherapy was found to significantly lower the occurrence of early relapses, while it did not reduce the rate of late lymphoma reoccurrence. Radiotherapy may well play an important role in initially improving the level of remission by effectively eradicating MRD after induction chemotherapy, while it simultaneously enhances the risk of clonal instability (Massenkeil et al, 2015) and thereby the possibility of a late relapsing malignancy. An answer to the question of whether late relapse represents 'true' relapse of a persistent clone or 'de novo' disease has been previously addressed, with some studies reporting patients to relapse with a completely different histology compared to the one found at time of primary diagnosis (Cabanillas et al, 1992; Nishiuchi et al, 1996; de Jong et al, 2003; Larouche et al, 2010; Vose et al, 2010) . Correspondingly, we also identified some patients with late relapse to have relapsed with a different, and more indolent, histology than DLBCL. This could reflect the presence of a pre-existing unrecognised indolent component, as previously postulated (Kluin et al, 1990; Larouche et al, 2010) , or it may represent a de novo malignancy.
The addition of the chimeric monoclonal anti-CD20 antibody rituximab to standard chemotherapeutic treatment of DLBCL has significantly improved the overall outcome of this disease (Coiffer, 2005; Pfreundschuh et al, 2011) . Similarly, earlier studies have demonstrated that the use of rituximab enhances the long-term overall survival and progression-free survival compared to treatment with chemotherapy alone . However, to the best of our knowledge, the present study represents the first report on the association between the upfront use of rituximab and the risk of late relapse in patients with DLBCL. The results of our study suggest that using an immunochemotherapy induction, consisting of rituximab in combination with an anthracycline-containing chemotherapy regimen, not only lowers the risk of early relapse, but also that of late relapses defined as occurring after a minimum of 5 years in CR. We found this to be true for both men and women. However, an additional finding was significantly higher rates of late relapse in women treated with rituximab compared to men -a difference that was not observed when comparing non-rituximab treated patients with late relapse. These results can, to some extent, be regarded as contradictory to findings reported by other groups, where the use of rituximab has proven of greater benefit to females compared to males (Riihijarvi et al, 2011; Horesh & Horowitz, 2014; Pfreundschuh et al, 2014) . Earlier studies have demonstrated a faster clearance of rituximab in males compared to females, which is considered a major contributing factor for the superior response rate observed in females (Muller et al, 2012) . In fact, this superior response to rituximab in females has been verified in other diseases besides non-Hodgkin lymphoma, e.g. rheumatoid arthritis and idiopathic membranous nephropathy (Ruggenenti et al, 2003; Ng et al, 2005) .
The observed relationship between female gender and rituximab with regard to late relapse is not readily explained. When addressing the age of female patients with late relapse who had received rituximab, no significant difference was found, indicating that hormonal status (i.e. pre-versus post-menopausal) did not seem to have an impact on the outcome.
The biological background for the observation of a possible connection between treatment with rituximab and the lowered risk of late relapse remains to be clarified. Similarly, an association between female gender, treatment with rituximab, and a higher incidence of late relapse warrants confirmation in independent cohorts. contribution in keeping the Danish haematology registers updated.
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